Articles

High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance

Hematology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid
Hematology, Hospital Ramon y Cajal, Madrid
Hematology, Hospital Miguel Servet, Zaragoza
Hematology, Hospital Universitario Dr Peset, Valencia
Hematology, Institut Català d’Oncologia, L’Hospitalet de Llobregat, Barcelona
Hematology, Hospital Universitario de Getafe, Madrid
Hematology, Hospital de Jerez de la Frontera, Jerez
Fundación Hospital de Alcorcón, Madrid
Hospital Universitario Marqués de Valdecilla, Servicio de Hematologia, Santander
Department of Hematology, Hospital Doce de Octubre, Madrid
Hematology, Hospital Morales Meseguer, Murcia
Hematology, CHU Juan Canalejo, A Coruña
Hematology, Hospital Txagorritxu, Vitoria
Hematology, Hospital Francesc Borja, Valencia
Hematology, Hospital La Paz, Madrid
Hematology, Hospital San Pedro de Alcantara, Caceres
Hematology, Hospital Universitario La Fe, Valencia
Hematology, Hospital Universitario Puerta del Mar, Cadiz
Hematology, Hospital de Sagunto, Valencia
Hematology, Hospital Madrid Norte Sanchinarro, Madrid
Hematology, Hospital General Castellon, Castellon
Hematology, Hospital Regional Universitario de Málaga, Málaga
Hematology, Hospital Clínico Universitario San Carlos, Madrid
Hematology, Hospital General de Móstoles, Madrid
Roche Farma, S.A., Madrid
Hematology, Hospital Universitario Príncipe Asturias, Madrid
Hematology, University Hospital of Salamanca-IBSAL, CIBERONC, USAL-CSIC, CIC-IBMCC, Salamanca
Hematology, Hospital Universitario Dr Peset, Valencia
Hematology, Consorcio Hospital General Universitario, Valencia
Hematology, Hospital Universitario de Getafe, Madrid, Spain
Vol. 104 No. 11 (2019): November, 2019 https://doi.org/10.3324/haematol.2018.204891